Multilineage hematopoietic reconstitution potential of enriched HSCs and their ex vivo expanded progeny
| Engrafted Compartment . | Sca-1+c-kit+Lin− . | Expanded Product . | Expanded Product + AcSDKP . | |||
|---|---|---|---|---|---|---|
| 1° Recipients (n = 7) . | 2° Recipients (n = 7) . | 1° Recipients (n = 25) . | 2° Recipients (n = 19) . | 1° Recipients (n = 20) . | 2° Recipients (n = 7) . | |
| Peripheral blood, % donor: | ||||||
| Total leukocytes | 91 ± 2 | 75 ± 4 | 85 ± 3 | 54 ± 6 | 93 ± 1 | 44 ± 3 |
| B cells | 98 ± 1 | 50 ± 9 | 93 ± 2 | 66 ± 6 | 98 ± 1 | 53 ± 4 |
| T cells | 77 ± 4 | 51 ± 4 | 72 ± 3 | 48 ± 5 | 81 ± 3 | 37 ± 3 |
| Myeloid cells | 91 ± 3 | 66 ± 7 | 76 ± 4 | 40 ± 7 | 87 ± 3 | 29 ± 6 |
| Marrow, % of normal: | ||||||
| Cells/femur | 115 ± 14 | 42 ± 11 | 70 ± 7 | 47 ± 5 | 65 ± 7 | 39 ± 5 |
| CFCs/femur | 122 ± 11 | 90 ± 15 | 230 ± 23 | 99 ± 13 | 186 ± 25 | 84 ± 11 |
| Engrafted Compartment . | Sca-1+c-kit+Lin− . | Expanded Product . | Expanded Product + AcSDKP . | |||
|---|---|---|---|---|---|---|
| 1° Recipients (n = 7) . | 2° Recipients (n = 7) . | 1° Recipients (n = 25) . | 2° Recipients (n = 19) . | 1° Recipients (n = 20) . | 2° Recipients (n = 7) . | |
| Peripheral blood, % donor: | ||||||
| Total leukocytes | 91 ± 2 | 75 ± 4 | 85 ± 3 | 54 ± 6 | 93 ± 1 | 44 ± 3 |
| B cells | 98 ± 1 | 50 ± 9 | 93 ± 2 | 66 ± 6 | 98 ± 1 | 53 ± 4 |
| T cells | 77 ± 4 | 51 ± 4 | 72 ± 3 | 48 ± 5 | 81 ± 3 | 37 ± 3 |
| Myeloid cells | 91 ± 3 | 66 ± 7 | 76 ± 4 | 40 ± 7 | 87 ± 3 | 29 ± 6 |
| Marrow, % of normal: | ||||||
| Cells/femur | 115 ± 14 | 42 ± 11 | 70 ± 7 | 47 ± 5 | 65 ± 7 | 39 ± 5 |
| CFCs/femur | 122 ± 11 | 90 ± 15 | 230 ± 23 | 99 ± 13 | 186 ± 25 | 84 ± 11 |
Lethally irradiated Ly-5.1 mice were transplanted with 103 Sca-1+c-kit+Lin−BM cells (Ly-5.2+) or their entire expanded progeny (approximately 2 × 106 cells) generated after 1 week of serum-free culture in IL-6, IL-11, G-CSF, SCF, FLK, and TPO. Some recipients of expanded cells were simultaneously injected with 10 or 100 μg AcSDKP. Primary mice were analyzed after 4 months. Secondary recipients, receiving a transplant of primary BM cells (0.5 femur/mouse), were analyzed 10 weeks later. Data shown are the mean ± SEM percentage of Ly-5.2+ cells detected in each blood cell compartment and the percentage of normal femoral cellularity and CFC content compared to 4 age-matched B6.SJL mice.